Abstract:DEAR EDITOR, Severe coronavirus disease 2019 (COVID19) is a well-recognized cause of morbidity and mortality across rheumatic diseases [1], and vaccines will play an important role in preventing illness. Immunosuppressive agents are commonly used in the treatment of rheumatological diseases, and among them, anti-CD-20 depleting therapies can result in an impaired humoral response to vaccines [2]. We had previously reported a case of COVID-19 vaccine failure in a patient on ocrelizumab therapy, an anti-CD19 mAb [3]. Here, we report another case of vaccine failure, this time in a patient on rituximab, an anti-CD20 mAb.A 73-year-old Caucasian male presented with nasal congestion, productive cough, myalgias and malaise of 4 days duration. Five weeks before, he had completed a two-dose series of the Pfizer-BioNTech COVID-19 vaccine given 21 days apart. He had a history of cryptogenic organizing pneumonia, intermittent asthma, type II diabetes mellitus, hyperlipidaemia and coronary artery disease. He was diagnosed with cryptogenic organizing pneumonia 2 years earlier, which was initially treated with prednisone and switched to rituximab owing to an inadequate treatment response. He was scheduled for i.v. rituximab infusion therapy at a dose of 375 mg/m every 6 months, and his last dose was administered 10 days after he had received the second dose of the vaccine. His medications included metoprolol succinate, atorvastatin, ezetimibe, metformin, sitagliptin, and a budesonide and formoterol inhaler. There were no known allergies. The patient is retired and lives in New York City. Since the start of the COVID-19 pandemic, he had restricted his participation in social activities and wore a face mask in public. He denied any history of alcohol, tobacco or illicit drug use. On examination, the patient appeared comfortable. Vitals signs were within normal limits. His respiratory effort and breath sounds were normal, as was the remainder of the physical examination. He tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via an RT-PCR nasopharyngeal swab. Given the high risk of progression to severe COVID-19 disease owing to his age and comorbidities, bamlanivimab and etesivimab, an mAb cocktail against SARS-CoV-2 was administered uneventfully. Serological testing was performed before the mAb cocktail infusion with two separate assays, assessing the immunological response to the spike and nucleocapsid protein of SARS-CoV-2, respectively. He tested negative for antibodies to both the spike (S) and nucleocapsid (N) antigens. He reported resolution of his symptoms 3 days after the infusion. Rituximab is an anti-CD20 mAb that binds to the CD20 antigen on the B cell surface, activating complement-dependent B cell cytotoxicity. B cells are believed to play a role in the development and progression of some autoimmune diseases. Signs and symptoms of those diseases are reduced by targeting B cells, and the progression of structural damage is delayed. Rituximab is widely used in patients with autoimmune disorders, haematological malignancies and vasculitides. The B-cell-depleting nature of rituximab therapy can lead to an impaired humoral immune response to vaccination. Studies have shown a blunted influenza vaccine response in patients on rituximab. The effect was most pronounced if vaccinated <2 months, with an improved response if vaccinated >6 months after rituximab therapy [4]. In the vaccine clinical guidance by the ACR [5], patients with a low or mitigatable risk of COVID-19 should have their vaccination scheduled 4 weeks before their next scheduled rituximab cycle; and after the completion of vaccination, should delay rituximab for 2–4 weeks after the second vaccine dose, if disease activity allows. A recent review article in Rheumatology recommended avoiding vaccination after rituximab, ideally for 6months; and if vaccination is imminent, consider delaying rituximab if there are no risks of organ failure or disease flare [6]. In our patient, rituximab was administered 10days after the last dose of the vaccine, and the patient developed clinical disease 5 weeks after completing vaccination. The absence of spike protein antibodies indicates an inadequate humoral response after 5weeks. Peak antibody response is expected 2weeks after the second dose of the COVID-19 vaccine [7]. The two-dose regimen of the vaccine confers a 95% protection against infection [8], and this could explain vaccine failure rather than use of rituximab. The half-life and prolonged B-cell-depleting effects of rituximab make it challenging to obtain an optimal window for vaccination. T-cell-mediated immunity after vaccination could have played a role in the mild nature of his illness, which was not accounted for by measuring only the humoral antibody response. Our case highlights the challenges in vaccinating patients on immunosuppressive drugs. Finding an optimal window and obtaining post-vaccination antibody titres might be beneficial. Patients should continue to maintain a high adherence to preventive measures Key message

Rituximab‐to‐vaccine interval on SARS‐CoV‐2 immunogenicity in children: The potential role of prior natural infection

Timing is essential: Humoral and cellular responses to SARS-CoV-2 vaccination in a cohort of patients with auto-immune diseases treated with rituximab

SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity

Evaluation of the Durability of the Immune Humoral Response to COVID-19 Vaccines in Patients with Cancer Undergoing Treatment or Who Received a Stem Cell Transplant

Covid-19 Vaccine Failure in A Patient on Rituximab Therapy

The immune response to Covid-19 mRNA vaccination among Lymphoma patients receiving anti-CD20 treatment

Hospitalised infections and rituximab administration among children and adolescents with systemic lupus erythematosus from 2009 to 2021

Hospitalisations and humoral COVID-19 vaccine response in vaccinated rituximab-treated multiple sclerosis patients

Hybrid immunity after BNT162b2 Covid-19 vaccine administration in children aged 5 to 11 years

Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations

Interferon-γ Release Assay in the Assessment of Cellular Immunity—A Single-Centre Experience with mRNA SARS-CoV-2 Vaccine in Patients with Juvenile Idiopathic Arthritis

Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial

Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al

Effectiveness and Safety of Rituximab for Children with Autoimmune Diseases of the Nervous System

Immunogenicity and safety of two doses of SARS‐CoV‐2 mRNA vaccine in kidney transplant recipients with low‐dose rituximab

Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression

Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies

Risk of SARS-CoV-2 Reinfection in Children Within the 12 Months Following Mild COVID-19: Insights From a Survey Study

Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies

Safety of Obinutuzumab in children with autoimmune encephalitis and early B cell repopulation on rituximab.

Effect of Immunosuppression on the Immune Response to SARS-CoV-2 Infection and Vaccination